REG - GSK PLC - Transaction in Own Shares

GSKAnnouncement

Mon 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250721:nRSU7518Ra&default-theme=true

RNS Number : 7518R  GSK PLC  21 July 2025

 

Transaction in own shares

GSK plc (the "Company") announces today acting through its corporate
stockbroker, Merrill Lynch International (the "Broker"), it has purchased the
following number of the Company's ordinary shares of 31¼ pence each.

 

 Date of purchase:                                                  18 July 2025
 Aggregate number of ordinary shares of 31¼ pence each purchased:   505,771
 Lowest price paid per share (GBp):                                 1,319.00p
 Highest price paid per share (GBp):                                1,360.50p
 Volume-weighted average price paid per share (GBp):                1,344.42p

 

The purchased shares will be held as Treasury shares.

Such purchase forms part of the Company's existing buyback programme and was
effected pursuant to the non-discretionary agreement entered into with the
Broker on 4 June 2025, as announced on 4 June 2025. Since 4 June 2025 the
Company has purchased 14,683,084 ordinary shares.

Following the above purchase, the Company will hold 232,817,467 ordinary
shares in treasury and have 4,082,566,813 ordinary shares in issue (excluding
Treasury shares).

The total number of voting rights in the Company is 4,082,566,813. This figure
may be used by shareholders as the denominator for the calculations by which
they will determine if they are required to notify their interest in, or a
change to their interest in, the Company under the Financial Conduct
Authority's Disclosure Guidance and Transparency Rules.

The Company confirms that, in accordance with DTR 5.5.1R, following the above
purchase the percentage of voting rights attributable to the ordinary shares
held in treasury is 5.70 per cent.

Detailed information of the individual trades made by the Broker on the London
Stock Exchange and the CBOE Europe Limited recognised investment exchange
(through its order books having market identification codes CHIX or BATE) as
part of the buyback programme can be found at:

http://www.rns-pdf.londonstockexchange.com/rns/7518R_1-2025-7-18.pdf (http://www.rns-pdf.londonstockexchange.com/rns/7518R_1-2025-7-18.pdf)

 
Ends

 

 GSK enquiries
 Media:               Tim Foley          +44 (0) 20 8047 5502  (London)
                      Kathleen Quinn     +1 202 603 5003       (Washington DC)

 Investor Relations:  Constantin Fest    +44 (0) 7831 826525   (London)
                      James Dodwell      +44 (0) 20 8047 2406  (London)
                      Mick Readey        +44 (0) 7990 339653   (London)
                      Steph Mountifield  +44 (0) 7796 707505   (London)
                      Jeff McLaughlin    +1 215 751 7002       (Philadelphia)
                      Frannie DeFranco   +1 215 751 3126       (Philadelphia)

 

Cautionary statement regarding forward-looking statements

GSK cautions investors that any forward-looking statements or projections made
by GSK, including those made in this announcement, are subject to risks and
uncertainties that may cause actual results to differ materially from those
projected. Such factors include, but are not limited to, those described in
the "Risk Factors" section in GSK's Annual Report on Form 20-F for 2024, and
GSK's Q1 Results for 2025.

 

Registered in England & Wales:

No. 3888792

 

Registered Office:

79 New Oxford Street

London

WC1A 1DG

 

 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  POSPKFBNFBKDFOD